Prevalence and clinical significance of cathepsin G antibodies in systemic sclerosis;Prevalenza e significato clinico degli anticorpi anti-catepsina G nella sclerosi sistemica

Reumatismo

Volumn 55, Issue 4, 2003, Pages 256-262

  Grypiotis, Panagiotis ^a   Ruffatti, A ^a   Cozzi, F ^a   Sinico, R A ^b   Tonello, M ^a   Radice, A ^b   Favaro, M ^a   Todesco, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

Author keywords

ANCA; Anti cathepsin G; Systemic sclerosis

Indexed keywords

ALCOHOL; CATHEPSIN G; CATHEPSIN G ANTIBODY; FORMALDEHYDE; NEUTROPHIL CYTOPLASMIC ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; CLINICAL FEATURE; CLINICAL RESEARCH; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; FREQUENCY ANALYSIS; HUMAN; IMMUNOFLUORESCENCE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PREVALENCE; SCLERODERMA; SERODIAGNOSIS; STATISTICAL SIGNIFICANCE; SYSTEMIC SCLEROSIS;

ADULT; AGED; AUTOANTIBODIES; CATHEPSINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; SCLERODERMA, SYSTEMIC; SERINE ENDOPEPTIDASES;

EID: 1642516238     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Van der Woude FJ, Rasmussen N, Lobatto S, Wiik A, Permin H, Van Es LA. Autoantibodies against neutrophils and monocytes: a new tool for diagnosis and a marker of disease activity in Wegener's granulomatosis. Lancet 1985; ii: 425-9.
2. Hagen EC, Mohamed RD, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998; 53: 743-53.
3. Savige J, Gillis D, Benson E, Davies D, Esnault V, Falk RJ, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999; 111: 507-13.
4. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651-7.
5. Cohen Tervaert JW, Goldschmeding R, Elema JD, Limburg PC, van der Giessen M, Huitemsa MG, et al. Association of autoantibodies to myeloperoxidase with different form of vasculitis. Arthritis Rheum 1990; 33: 1264-72.
6. Kuwana T, Sato Y, Saka M, Kondo Y, Miyata M, Obara K, et al. Anti-cathepsin G antibodies in the sera of patients with ulcerative colitis. J Gastroenterol 2000; 35: 682-9.
7. Halbwachs-Mecarelli L, Nusbaum P, Noel NH, Reumaux D, Erlinger S, Grunfeld JP, et al. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin Exp Immunol 1992; 90: 79-84.
8. Sobajima J, Ozaki S, Okazaki T, Osakada F, Sumita S, Mori K, et al. Anti-neutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis: anti-cathepsin G and a novel antibody correlate with a refractory type. Clin Exp Immunol 1996; 105: 120-4.
9. Kossa K, Coulthart A, Ives CT, Pusey CD, Hodgson HJF. Antigen specificity of circulating anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur J Gastroenterol Hepatol 1995; 7: 783-9.
10. Lindgren S, Nilsson S, Nasberger L, Verbaan H, Wieslander J. Anti-neutrophil cytoplasmic antibodies in patients with chronic liver disease: Prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease. J Gastroenterol Hepatol 2000; 15: 437-42.
11. Mulder AHL, Horst G, Van Leeuwen, Limburg PC, Kallenberg CGM. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis Arthritis Rheum 1993; 36: 1054-60.
12. de Bandt M, Meyer O, Haim T, Kahn MF. Antineutrophil cytoplasmic antibodies in rheumatoid arthritis patients. Br J Rheumatol 1996; 35: 38-43.
13. Savige JA, Chang L, Wilson D, Buchanan RRC. Autoantibodies and target antigens in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. Rheumatol Int 1996; 16: 109-14.
14. Uesugi H, Ozaki S, Sobajima J, Osakada F, Shirakawa H, Yoshida M, et al. Prevalence and characterization of novel P-ANCA,antibodies to the High Mobility Group non-histone Chromosomal Proteins HMG1 and HMG2, in systemic Rheumatic Diseases. J Rheumatol 1998; 25: 703-9.
15. Locht H, Skogh T, Wiik A. Characterization of autoantibodies to neutrophil granule costituents among patients with reactive arthritis, rheumatoid arthritis and ulcerative colitis. Ann Rheum Dis 2000; 59: 898-903.
16. Nishiya K, Chikazawa H, Hashimoto K, Miyawaki S. Antineutrophil cytoplasmic antibody in patients with primary Sjögren's syndrome. Clin Rheumatol 1999; 18: 268-71.
17. Schnabel A, Csernok E, Isenberg DA, Mrowka C, Gross WL. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Arthritis Rheum 1995; 18: 633-7.
18. Spronk PE, Bootsma H, Horst G, Huitema MG, Limburg PC, Tervaert JW, et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Br J Rheumatol 1996; 35: 625-31.
19. Nishiya K, Chikazawa H, Nishimura S, Hisakawa N, Hashimoto K. Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus in unrelated to clinical features. Clin Rheumatol 1997; 16: 70-5.
20. Zhao MH, Liu N, Zhang YK, Wang HY. Antineutrophil cytoplasmic autoantibodies (ANCA) and their target antigens in Chinese patients with lupus nephritis. Nephrol Dial Transplant 1998; 13: 2821-4.
21. Lesarve P, Nusbaum P, Halbwachs-Mecarelli L. Methods of detection of anticathepsin G autoantibodies in human. Adv Exp Med Biol 1993; 336: 257-61
22. Wong SN, Shah V, Dillon MJ. Antineutrophil cytoplasmic antibodies in Wegener's granulomatosis. Arch Dis Child 1998; 79: 246-50.
23. Zhao MH, Lockwood CM. Azurocidin is a novel antigen for anti-neutrophil cytoplasmic autoantibodies (ANCA) in systemic vasculitis. Clin Exp Immunol 1996; 103: 397-402.
24. Nassberger L, Sjoholm AG, Jonsson H, Sturfelt G, Akesson A. Autoantibodies against neutrophil cytoplasin components in systemic lupus erythematosus and in hydralazine-induced lupus. Clin Exp Immunol 1990; 81: 380-3.
25. Gross WL, Schmitt WH, Csernok E. Antineutrophil cytoplasmic autoantibody-associated diseases: a Rheumatologist's perspective. Am J Kidney Dis 1991; 18: 175-9.
26. Endo H, Hosono T, Kondo H. Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J Rheumatol 1994; 21: 864-70.
27. Akimoto S, Ishikawa O, Tamura T, Miyachi Y. Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis. Br J Dermatol 1996; 134: 407-10.
28. Kiraz S, Simsek H, Ertenli I, Benekli, Kadayifci A. Antineutrophil cytoplasmic antibodies in systemic sclerosis. Clin Rheumatol 1996; 15: 519-23.
29. Locke IA, Worrall JG, Leaker B, Black CM, Cambridge G. Autoantibodies to myeloperoxidase in systemic sclerosis. J Rheumatol 1997; 24: 86-9.
30. Merkel PA, Polisson RP, Chang Y, Skates SJ, Niles JL. Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med 1997; 126: 866-73.
31. Choi HK, Slot MC, Pan G, Weissbach CA, Niles JL, Merkel PA. Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. Arthritis Rheum 2000; 43: 2488-92.
32. Chikazawa H, Nishiya K, Matsumori A, Hashimoto K. Immunoglobulin isotypes of anti-myeloperoxidase and anti-lactoferrin antibodies in patients with collagen diseases. J Clin Immunol 2000; 20: 279-86.
33. Ruffatti A, Sinico RA, Radice A, Ossi E, Cozzi F, Tonello M, et al. Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. J Rheumatol 2002; 29: 918-23.
34. Pratesi F, Moscato S, Sabbatini A, Chimenti D, Bornbardieri S, Migliorini P. Autoantibodies specific for α-enolase in systemic autoimmune disorders. J Rheumatol 2000; 27: 109-15.
35. Bellisai F, Morozzi G, Bacarelli MR, Radice A, Sinico RA, Wieslander J, et al. Anticorpi anti-proteinasi 3 nella sclerosi sistemica (ScS) diffusa con impegno renale normotensivo: possono essere suggestivi di una sovrapposizione tra ScS e vasculite idiopatica? Reumatismo 2001; 53: 33-9.
36. Vàzquez-Del Mercado M, Mendoza-Topete A, Best-Aguilera CR, Garcia-De La Torre I. Diffuse alveolar haemorrhage in limited cutaneous systemic sclerosis with positive perinuclear antineutrophil cytoplasmic antibodies. J Rheumatol 1996; 23: 1821-3.
37. Carvajal I, Bernis C, Sanz P, Garcia A, Garcia-Vadillo A, Traver JA. Antineutrophil cytoplasmic autoantibodies (ANCA) and systemic sclerosis. Nephrol Dial Transplant 1997; 12: 576-7.
38. Omote A, Muramatsu M, Sugimoto Y, Hosono S, Murakami R, Tanaka H et al. Myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibodies-related scleroderma renal crisis treated with double-filtration plasmapheresis. Intern Med 1997; 36: 508-13.
39. Hillis GS, Khan IH, Simpson JG, Rees AJ. Scleroderma, D-penicillamine treatment, and progressive renal failure associated with positive antimyeloperoxidase antineutrophil cytoplasmic antibodies. Am J Kidney Dis 1997; 30: 279-81.
40. Kyndt X, Ducq P, Bridoux F, Reumaux D, Makdassi R, Gheerbrant, et al. Glomérulonéphrite extra capillaire avec anticorps anti-myeloperoxidase chez 2 malades ayant une sclérodermie systémique traitée par D-penicillamine. Presse Med 1999; 28: 67-70.
41. Anders HJ, Wiebecke B, Haedecke C, Sanden S, Combe C, Schlöndorff D. MPO-ANCA-Positive crescentic glomerulonephritis: A distinct entity of scleroderma renal disease? Am J Kidney Dis 1999; 33: 3E.
42. Villaverde V, Balsa A, Cabezas JA, Fernàndez-Prada M, Torre A, Mola EM. Normotensive renal failure in a patient with systemic sclerosis and p-antineutrophil cytoplasmic autoantibodies which developed into Paget's disease of bone after immunosuppressive therapy. Rheumatology 1999; 38: 190-1.
43. Katrib A, Sturgess A, Bertouch JV. Systemic sclerosis and antineutrophil cytoplasmic autoantibody-associated renal failure. Rheumatol Int 1999; 19: 61-3.
44. Yamashita K, Yorioka N, Kyuden Y, Naito T, Tanji C, Ueda C, et al. A case of CREST syndrome and myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin Nephrol 2000; 53: 296-300.
45. Maes B, Van Mieghem A, Messiaenen T, Kuypers T, Van Damme B, Vanrenterghem Y. Limited cutaneous systemic sclerosis associated with MPO-ANCA positive renal small vessel vasculitis of the microscopic polyangiitis type. Am J Kidney Dis 2000; 36: E16.
46. Harashima S, Yoshizawa S, Horiuchi T, Nakashima H, Niho Y, Kusaba T, et al. A case of systemic sclerosis with crescentic glomerulonephritis associated with perinuclear-antineutrophil cytoplasmic antibody (p-ANCA). Nihon Rinsho Meneki Gakkai Kaishi 1999; 22: 86-92.
47. Martinez Ara J, Picazo ML, Torre A, Pascual D, Diaz Rodriguez C, Rinon C. Progressive systemic sclerosis associated with anti-myeloperoxidase ANCA vasculitis with renal and cutaneous involvement. Nephrol 2000; 20: 383-6.
48. Mizutani A, Tanaka I, Katayama M, Oshima H, Komatsu Y, Asano S, et al. A case of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) related glomerulonephritis associated with systemic sclerosis treated by steroid pulse therapy: a case report. Ryumachi 2000; 40: 828-32.
49. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committeee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
50. Medsger TA, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 2159-67.
51. Wiik A. Delineation of a standard procedure for indirect immunofluorescence detection of ANCA. Acta Pathol Microbiol Immunol Scand 1989; 97 Suppl: 12-3.
52. Radice A, Vecchi M, Bianchi MB, Sinico RA. Contribution of immunofluorescence to the identification and characterization of anti-neutrophil cytoplasmic autoantibodies. The role of different fixatives. Clin Exp Rheumatol 2000; 18: 707-12.
53. Goel MS, Diamond SL. Neutrophil enhancement of fibrin deposition under flow through platelet-dependent and -indipendent mechanisms. Artherioscler Thromb Vasc Biol 2001; 21: 2093-8.
54. Miyasaki KT, Bodeau AL, Pohl J, Shafer WM. Bactericidal activities of synthetic human leukocyte cathepsin G-derived antibiotic peptides and congeners against Actinobacillus actinomycetemcomitans and Capnocytophaga sputigena. Antimicrob Agents Chemother 1993; 37: 2710-5.